RESPIRATORY SYNCYTIAL VIRUS (RSV)

This study tests a new vaccine to prevent respiratory syncytial virus (RSV) infections in adults aged 60 and older. RSV can cause serious lung disease in older people. The trial will involve 25,000 participants who will receive either the vaccine or a placebo, and researchers wil…

This early-stage study tests the safety and immune response of new vaccines for respiratory syncytial virus (RSV) and a type of bird flu (H5N1) in 570 healthy adults aged 18 to 49. Participants will receive different vaccine formulas and be monitored for side effects and antibody…

This study looks at how well the RSV vaccine Arexvy works in 170 adults with weakened immune systems. Participants will receive up to 3 vaccine doses over a year and be monitored for side effects and immune response. The goal is to find the best dosing schedule to protect this hi…

This study tests an RSV vaccine in adults aged 18-59 who have health conditions like chronic lung, heart, or kidney disease that put them at higher risk for severe RSV. The goal is to see if the vaccine triggers a strong immune response and is safe. Participants receive one shot …

This study checks the safety of a monthly injection called palivizumab in infants and children under 24 months who are at high risk for severe RSV disease. About 138 participants will receive up to 5 injections over the study period. The goal is to see how safe the drug is and tr…

This early-stage trial tests a new injection called SIBP-A16 in 140 healthy adults aged 18 to 45. The goal is to see if it is safe and how the body processes it. This is a first step toward possibly preventing RSV, a common respiratory virus that can be serious for some people.

This study will test 10,000 people in Cambodia for antibodies against 57 different infectious diseases, including dengue, flu, and malaria. The goal is to map where and how these diseases spread, so health officials can design better prevention strategies. Participants must live …